Advancis Pharmaceutical Corporation

Shire Laboratories, Inc.

Shionogi, Inc.

Middlebrook Pharmaceuticals, Inc.

Sandra E Wassink

Edward M Rudnic

Donald J Treacy, Jr

James D Isbister

Beth A Burnside

Henry H Flanner

Richard Alan Couch

Jill E Pinkett

Bruce X Cao

Rong-Kun Chang

John A McCarty

Colin E Rowlings

Donald J Treacy

George W Belendiuk

Matt R Baker

John A Bonck

James D Isbiter

Lisa R White

An antibiotic product is comprised of at least two dosages forms, each of which has a different release profile, with the Cfor the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as one or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cat different times.

Once a day amoxicillin product comprising immediate and delayed release dosage forms

Compositions and methods for making robust pellets that contain a high percentage, by weight, of active drug agent, and which also contain additional components that enhance the absorption and solubility of the active drug agent within the gastrointestinal tract (GI tract) without diminishing the robust nature of the pellet, are disclosed.

Robust pellet

A pharmaceutical tablet comprising an immediate release portion containing an active ingredient and a delayed release portion, wherein the delayed release portion comprises an enteric-coated layer and within the enteric-coated layer there is at least one member selected from the group consisting of enteric-coated microparticle dosage forms containing an active ingredient and enteric-coated mini-tablet dosage forms containing an active ingredient, is disclosed.

Tablet for pulsed delivery

An antifungal product is comprised of at least three dosages forms, each of which has a different release profile, with the Cfor the antifungal product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cat different times.

Antifungal once-a-day product, use and formulation thereof

An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cfor the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cat different times.

Antiviral product, use and formulation thereof

An anti-fungal product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cfor the anti-fungal product being reached in less than about twelve hours after initial release of anti-fungal from the product.

Multiple-delayed release antifungal product, use and formulation thereof

An antineoplastic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cfor the antineoplastic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cat different times.

Antineoplastic product, use and formulation thereof

An anti-neoplastic product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cfor the anti-neoplastic product being reached in less than about twelve hours after initial release of anti-neoplastic from the product.

Multiple-delayed release anti-neoplastic product, use and formulation thereof

An anti-viral product is comprised of at least three delayed release dosage forms, each of which has a different release profile, with the Cfor the anti-viral product being reached in less than about twelve hours after initial release of anti-viral from the product.

Multiple-delayed release anti-viral product, use and formulation thereof

An antibiotic product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cfor the antibiotic product being reached in less than about twelve hours.

Multiple-delayed released antibiotic product, use and formulation thereof

Disclosed are antibiotic products for delivering at least two different antibiotics, wherein the products are comprised of at least three or four dosage forms with different release profiles and the at least two different antibiotics comprise at least one protein synthesis inhibiting antibiotic and at least one non-protein synthesis inhibiting antibiotic.

Antibiotic composition

An anti-fungal product for delivering at least two different anti-fungals that is comprised of three dosage forms with different release profiles with each anti-fungal being present in at least one of the dosage forms.

Anti-fungal composition

Disclosed is an osmotic pharmaceutical delivery system comprising (a) a semi-permeable wall that maintains its integrity during pharmaceutical delivery and which has at least one passage therethrough; (b) a single, homogeneous composition within said wall, which composition consists essentially of (i) a pharmaceutically active agent, (ii) at least one non-swelling solubilizing agent which enhances the solubility of the pharmaceutically active agent; (iii) at least one non-swelling osmotic agent and (iv) a non-swelling wicking agent dispersed throughout the composition which enhances the surface area contact of the pharmaceutical agent with the incoming aqueous fluid.

Osmotic drug delivery system

An antibiotic product, in particular a tetracycline, such as doxycycline, is comprised of at least three dosages forms, each of which has a different release profile, with the C for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a C at different times.

Growing community of inventors

Frederick, MD, United States of America

Sandra E Wassink